Azitra is trading at $0.79, down 12.89%, extending its recent decline. - Shares closed at $0.90 on October 28, after $1.12 on October 27. - On October 29, Azitra announced expanded ATR-04 trial eligibility, including rashes associated with KRAS and MEK inhibitors, and shorter washout periods; reporting does not establish this as the cause of the decline. - Broader markets are lower, with the Nasdaq Composite down 1.44%; available evidence does not confirm a direct link.